financetom
Business
financetom
/
Business
/
International flight opearations from Kushinagar airport in next 2 months: UP CM
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
International flight opearations from Kushinagar airport in next 2 months: UP CM
Sep 6, 2020 10:56 PM

International flight operations from the Kushinagar airport will commence in the next months, Uttar Pradesh Chief Minister Yogi Adityanath said Sunday, according to a state government statement. The Union Cabinet had on June 24 approved the Kushinagar airport’s status as an international facility, stating it will offer improved connectivity to the important Buddhist pilgrimage site.

Adityanath Sunday met Civil Aviation Minister Hardeep Singh Puri at Kushinagar and discussed the progress in the project. Within the next two months, International flights will commence operations from this airport, Yogi was quoted as saying in the government statement. Once this airport begins operating international flights, it will become the fourth international facility in the state. At present, two international airports — Chaudhary Charan Singh International Airport at Lucknow and Lal Bahadur Shastri International Airport at Varanasi — are operational in the state, the UP government said.

An international airport is under construction at Gautam Buddh Nagar. ”Kushinagar is the Central point of Buddhist circuit. A large number of followers of Buddhism come here, as this is the place where Lord Buddha attained Mahanirvana. He had given his first sermon at Sarnath, Adityanath said.

People from Sri Lanka, Thailand, Laos, Japan, Singapore and other countries wanted air connectivity with Kushinagar, he said. Puri said, ”Permission for flight service has been given on 18 new routes. Apart from this, other airports will be constructed/developed.”

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Ferguson Maintains FY25 Guidance Amid Tough Market, Q1 Misses Estimates
Ferguson Maintains FY25 Guidance Amid Tough Market, Q1 Misses Estimates
Dec 10, 2024
Ferguson Enterprises Inc. ( FERG ) shares are trading lower after the company reported first-quarter results. The company reported net sales of $7.77 billion, which was 0.8% higher year over year, missing the consensus of $7.83 billion. Organic revenue fell by 0.3%, with a 1.1% negative impact from acquisition growth. Net sales in the U.S. business increased by 0.5%, while that in Canada grew by 6.3%. Gross margin contracted by 10 basis points...
Why Is Cancer-Focused Chimerix Stock Trading Higher On Tuesday?
Why Is Cancer-Focused Chimerix Stock Trading Higher On Tuesday?
Dec 10, 2024
On Monday, Chimerix ( CMRX ) announced that, following extensive dialogue with the FDA, the company plans to submit a complete New Drug Application (NDA) seeking accelerated approval for dordaviprone for recurrent H3 K27M-mutant diffuse glioma in the U.S. before year-end. A glioma is a tumor that originates in the glial cells of the brain or spinal cord and is the...
Broadcom Launches Premium Version of Bitnami, Names Arrow Electronics as Distributor
Broadcom Launches Premium Version of Bitnami, Names Arrow Electronics as Distributor
Dec 10, 2024
09:41 AM EST, 12/10/2024 (MT Newswires) -- Broadcom ( AVGO ) said Tuesday it's launching a commercial version of Bitnami and has named Arrow Electronics ( ARW ) as a global distributor of the product. Broadcom ( AVGO ) said Bitnami is a free catalog of open-source software and the premium version of the product has security-enhancing features. Arrow will...
NewAmsterdam Pharma Says Phase 3 Trial of Obicetrapib Reaches Primary Endpoint; Shares Jump Pre-Bell
NewAmsterdam Pharma Says Phase 3 Trial of Obicetrapib Reaches Primary Endpoint; Shares Jump Pre-Bell
Dec 10, 2024
09:28 AM EST, 12/10/2024 (MT Newswires) -- NewAmsterdam Pharma ( NAMS ) said Tuesday a phase 3 trial assessing obicetrapib in people with established atherosclerotic cardiovascular disease and/or heterozygous familial hypercholesterolemia reached its primary endpoint. The company's shares surged 35% in recent premarket activity. The primary endpoint was the least-squares mean of the percent change in LDL-C from baseline to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved